#021 Chris Moreau: don't let fear stop science

#021 Chris Moreau: don't let fear stop science

Author: Ray Christian December 2, 2021 Duration: 29:15
Summary: We talk with Chris Moreau — CEO of Algernon Pharmaceutics— about psychedelics for neural growth, drug repurposing, and the path to clinical trial approvals. Highlights: — NUGGET AND A NOODLE: UK prime minister ponders psychedelics, tax revenue from magic mushrooms (0:28) — psychedelics helping brain neurons grow (2:20) — can psychedelics heal the brain or make you smarter? (8:40) — drug repurposing to focus on stroke, chronic cough and IPF (12:37) — the brain reboot (19:50...

Hosted by Ray Christian, Psy Diaries sits at the curious intersection of clinical science and profound personal transformation. This isn't just another health podcast; it's a series of deep, often surprising conversations with doctors, researchers, and therapists who are actively exploring the frontiers of the mind. You'll hear firsthand accounts and rigorous analysis about the resurgence of psychedelic compounds, moving beyond sensational headlines to understand the real mechanisms at play. Episodes delve into how these ancient and modern substances are being re-examined for mental health, from alleviating deep-seated trauma to facilitating those ineffable mystical experiences that can redefine a person's worldview. The discussion naturally extends to the broader cultural shift-the so-called mushroom renaissance-and its ripple effects on therapy, spirituality, and even our legal frameworks. Tune in for a thoughtful, evidence-informed dialogue that respects both the potency of the compounds and the complexity of the human psyche, all while navigating the practical realities of integrating these discoveries into our daily lives and society. Each episode aims to replace stigma with understanding, offering nuanced perspectives on how these powerful tools affect not just individual minds, but the collective world around us.
Author: Language: en-us Episodes: 49

Psy Diaries
Podcast Episodes
#008 Marik Hazan interview: two paths for the psychedelic renaissance [not-audio_url] [/not-audio_url]

Duration: 33:18
We talk with Marik Hazan, CEO of Tabula Rasa Ventures, about psychedelics for creativity, the impact of money on the industry. Plus Marik's take on the good, bad, and the ugly of the psychedelic industry. Highlights — TH…
#007 Interview with Adam Deffett: less guns, more research lab coats [not-audio_url] [/not-audio_url]

Duration: 28:42
We talk with Adam Deffett, CEO of Ketamine One, about their plans for psychedelic research, and how VR and wearables will play a role. Plus thoughts on the changing perspective of psychedelics & mental health. Highlights…